A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly gemcitabine in elder patients (, 75) with previously untreated advanced non-small cell lung cancer. Primary objective is to determine the objective response rate (CR+PR by RECIST criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (, 76 years) who have received no prior treatment for non-small lung cancer. As secondary objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin combination chemotherapy, progression-free survival and overall survival will be evaluated in both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly single gemcitabine.. The study hypothesis is that biweekly combination chemotherapy of gemcitabine plus carboplatin may improve the efficacy. ...
Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to
OBJECTIVES: To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.. METHODS: 8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity. The effect of the combinations was also evaluated by measuring the inhibition of cells grown as spheroids.. RESULTS: Navitoclax exhibited modest (IC(50)=3-8 μM) single agent potency. Antagonism between carboplatin and paclitaxel was evident in Ovcar-4, Ovcar-8 and Skov-3 cells. Drug combinations including navitoclax with carboplatin and/or paclitaxel showed significantly less antagonism, or even synergy, in several cell lines than carboplatin/paclitaxel alone. Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells. Combinations of navitoclax, carboplatin and paclitaxel showed more than additive activity ...
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous NSCLC) bevacizumab (B). Anticipated time on study treatment is until disease progression or intolerable toxicity occurs. Participants in placebo arms with disease progression may cross over to open-label active pictilisib ...
Looking for online definition of Paclitaxel/Carboplatin or what Paclitaxel/Carboplatin stands for? Paclitaxel/Carboplatin is listed in the Worlds largest and most authoritative dictionary database of abbreviations and acronyms
An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effects observed for carboplatin. The analysis was reported by Hahnen et al in JAMA Oncology. GeparSixto showed the addition of neoadjuvant carboplatin to anthracycline, taxane, and bevacizumab (Avastin) increased pathologic complete response rates among all patients.. Study Details The current analysis included 291 patients, of whom 146 received carboplatin. Pathogenic BRCA1 and BRCA2 germline mutations were present in 50 patients (17.2%), including 26 patients who received carboplatin and 24 patients who did not.. Pathologic Complete Response Rate. The pathologic complete response rate was 56.8% in the carboplatin group vs 41.4% in the group that did not receive carboplatin (odds ratio [OR] = 1.87, P = .009). ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
To report the results of combined chemoradiation (CCRT) with cisplatin versus carboplatin in locally advanced cervical carcinoma. From 2009 to 2013, 255 patients with stage IIB-IVA cervical carcinoma, according to FIGO staging were prospectively assigned to be treated with pelvic radiotherapy followed by brachytherapy given concurrently with cisplatin or carboplatin in the treatment of locally advanced cervical cancer. Treatment outcomes and toxicitiy were evaluated. Two-hundred and thirteen patients could be evaluated. At a median follow-up time of 43 months (6-69 months), the 3-year local control, disease-free survival, metastasis-free survival and overall survival rates were 93, 80.8, 85.0 and 87.3 %, respectively. No statistical difference in terms of local control, disease-free survival, metastasis-free survival and overall survival rates between cisplatin and carboplatin treatments was observed in this study. Eighty-six percents of the patients in the carboplatin group could receive more than 4
The combination of carboplatin-paclitaxel is a global standard following recent consensus recommendations [20, 4]. Although this treatment is highly effective, most patients recur. The majority are platinum-sensitive at first relapse, thus, candidates for re-treatment with platinum. Indeed, these patients will be generally re-treated with a platinum-taxane combination, especially in the light of recent trials showing advantage over platinum monotherapy [9]. However, the cumulative neurotoxicity of both drugs, as well as the increased risk of neurotoxicity for patients in relapse and the further experience of alopecia, are essential considerations when selecting second-line therapy [21]. As treatment at relapse is rarely curative, toxicity, tolerance, ease of administration and QoL should be interrelated to efficacy and survival prolongation when novel platinum-based combinations are evaluated for patients with platinum-sensitive OC.. This study was originally designed in 1999, in an era when ...
Materials and methods The overall number of patients and carboplatin courses, sex, age, diagnosis and percentage overdose were extracted from the Farmis database on cytostatics management, from January 2011 to September 2013. Overdoses were designated: carboplatin dosing ,900 mg for a target AUC = 6; carboplatin dosing ,750 mg for a target AUC = 5; carboplatin dosing ,600 mg for a target AUC = 4. In the event of overdosing (Common Terminology Criteria for Adverse Events (CTCAE) criteria), blood tests were sought before the next round of treatment and the need to delay the chemotherapy treatment were evaluated.. ...
Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...
Carboplatin, Carboplatin Suppliers Directory - Find variety Carboplatin Suppliers, Manufacturers, Companies from around the World at ,
Find out about the science and chemistry of Carboplatin (Paraplatin), see colourful images of Carboplatin and explore interactive 3D molecules of Carboplatin
Purpose: Patupilone is a microtubule-targeting chemotherapeutic agent with clinical activity in a broad range of taxane-sensitive/resistant tumor types. The present phase lb study examined the safety/tolerability and pharmacokinetics of patupilone in combination with carboplatin in patients with advanced solid tumors. Experimental Design: Patients with advanced cancer received patupilone via a 5- to 10-min i.v. infusion at doses of 3.6 to 6.0 mg/m(2) q3w, immediately followed by carboplatin area under the curve (AUC) 5 or 6 mg/mL/min. Results: Of the 37 patients enrolled, the majority previously received taxanes (81%) and/or platinum-containing drugs (97.3%). The maximum tolerated dose (MTD) of patupilone with carboplatin AUC 6 was 4.8 mg/m2; additional patients were enrolled to consolidate experience at this dose. Of the 22 patients who received the MTD, the most common nonhematologic adverse events were fatigue in six (27.3%) and diarrhea, nausea, vomiting, abdominal pain, and neuropathy in ...
nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial Cesare Gridelli,1 Tianlei Chen,2 Amy Ko,2 Mary E O’Brien,3 Teng Jin Ong,4 Mark A Socinski,5 Pieter E Postmus6 1Division of Medical Oncology, S. G. Moscati Hospital, Avellino, Italy; 2Biostatistics, Celgene Corporation, Summit, NJ, USA; 3Medical Oncology, Royal Marsden Hospital, London, UK; 4Medical Affairs, Celgene Corporation, Summit, NJ, USA; 5Lung Cancer & Esophageal Cancer, Florida Hospital Cancer Institute, Orlando, FL, USA; 6Pulmonary Diseases, Clatterbridge Cancer Center, Liverpool, UK Background: Limited data on elderly patients with squamous advanced non-small cell lung cancer (NSCLC) preclude optimal treatment. Here, we report the outcomes of a retrospective analysis of a subset of patients ≥70 years with squamous histology from the Phase III trial that evaluated nab-paclitaxel/carboplatin vs paclitaxel/carboplatin. Patients and methods
This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC). Eligible patients had Stage III or IV (oligometastatic) NSCLC. Patients received XRT to 63 Gy in standard fractionation. Patients received concurrent carboplatin (AUC = 6) during weeks 1 and 5 of XRT, and pemetrexed during weeks 1, 3, 5, and 7 of XRT. The starting dose level (level 1) of pemetrexed was 300 mg/m2. Following the finding of dose limiting toxicity (DLT) in dose level 1, an amended dose level (level 1A) continued pemetrexed at 300 mg/m2, but with involved field radiation instead of extended nodal irradiation. Consolidation consisted of carboplatin (AUC = 6) and pemetrexed (500 mg/m2) q3 weeks × 2 -3 cycles. Eighteen patients were enrolled. Fourteen patients are evaluable for toxicity analysis. Of the initial 6 patients treated on dose level 1, two experienced DLTs (one grade
article{7b211b82-b7cf-45eb-9b6c-526d9db736a8, abstract = {Chemotherapy resistance remains a major obstacle to successful treatment of ovarian cancer patients. Therefore, increased knowledge of underlying mechanisms and identification of predictive factors are of great importance. Standard treatment for ovarian carcinoma is surgery followed by platinum-based chemotherapy. In this study, we aimed to search for genes or genomic regions involved in platinum resistance in ovarian carcinoma. Array-based comparative genomic hybridization (CGH) was used to identify genetic alterations in 32 early-stage epithelial ovarian carcinomas homogeneously treated with single-agent carboplatin. The arrays contain 33,370 bacterial artificial chromosome (BAC) clones and form a contiguous and tiling coverage of the human genome with an average resolution of similar to 100 kb. We found certain genetic changes associated with carboplatin response. Gains in 1q25.1-q41 were significantly more frequent in ...
Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combinati
TY - JOUR. T1 - Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy. T2 - An Eastern Cooperative Oncology Group (ECOG) study (E4508). AU - Hanna, Nasser H.. AU - Dahlberg, Suzanne E.. AU - Kolesar, Jill M.. AU - Aggarwal, Charu. AU - Hirsch, Fred R.. AU - Ramalingam, Suresh S.. AU - Schiller, Joan H.. PY - 2015/7/1. Y1 - 2015/7/1. N2 - BACKGROUND Preclinical evidence supports the clinical investigation of inhibitors to the insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) either alone or in combination as treatment for patients with non-small cell lung cancer (NSCLC). METHODS Patients with chemotherapy-naïve, advanced NSCLC who had an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomized to receive carboplatin intravenously at an area ...
carboplatin 41575-94-4 MSDS report, carboplatin MSDS safety technical specifications search, carboplatin safety information specifications ect.
It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects. While you are being treated with carboplatin, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctors approval. Carboplatin may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine since there is a chance they could pass the polio virus on to you. Also, avoid persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, you should consider wearing a protective face mask that covers the nose and mouth. Carboplatin can temporarily lower the number of white blood cells in your blood, increasing the chance of ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
The combination of carboplatin plus paclitaxel was less toxic and trended toward better survival as compared with 5-fluorouracil and cisplatin.
Adding aprepitant to palonosetron and dexamethasone provided no improvement in carboplatin-induced emesis in non-small cell lung cancer (NSCLC).
AIM: To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial. PATIENTS AND METHODS: The international non-inferiority trial enrolled women with ROC that relapsed ,6 months following first- or second-line platinum- and paclitaxel-based therapies. Patients were randomised to CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) and stratified by treatment-free interval (TFI). In this analysis, patients with a TFI,24 months were analysed separately for progression free survival (PFS), the primary endpoint of CALYPSO, overall survival (OS) and safety. RESULTS: A total of 259 very platinum-sensitive patients were included (n=131, CD; n=128, CP). Median PFS was 12.0 months for the CD arm and 12.3 months for CP [HR=1.05 (95% CI, 0.79-1.40); P=0.73 for superiority] and median OS was 40.2 months for CD and 43.9 for CP [HR=1.18 (95% CI 0.85-1.63); P=0.33 for superiority]. Overall response ...
This paper investigates a longitudinal tumour response model to describe and predict the response of the primary lesion in non-small cell lung cancer (Figure 2, taken from here) to gemcitabine (with carboplatin) chemotherapy. A total of 202 tumour size measurements from 56 patients were used to establish the pharmacodynamic model for tumour response. Gemcitabine was infused at either a fixed dose rate of 750mg/m2 over 75 mins or 1000mg/m2 over 30 mins on days 1 and 8 every 3 week in stage IIIB or IV non-small cell lung cancer patients. Carboplatin dose was administered as a 1hour infusion just before gemcitabine on day 1 of every cycle to patients. The pharmacokinetic exposure variables are the Gemcitabine dose and the AUCs (concentration-time curve) corresponding to each dose given, over the entire duration of treatment. Serial measurements of the largest dimension of the primary tumour were done on radiological images using electronic calipers at baseline after cycles 2, 4 and 6 and bimonthly ...
To assess high-dose carboplatin chemotherapy with or without paclitaxel with filgrastim mobilized peripheral blood progenitor cell (PBPC) support in a phase I/II study, a total of 21 patients with mostly chemonaive disease received four cycles of high-dose chemotherapy. Cycle 1 (cyclophosphamide, 6 …
This study will compare the efficacy and tolerability of paclitaxel + carboplatin versus gimeracil/oteracil/tegafur + carboplatin in patients with advanced
Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.: Th
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment sensitivity would be valuable in order to identify responders from non-responders. In this study we describe the non-invasive PET imaging of glucose uptake and cell proliferation using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3-[(18)F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of human ovarian cancer treated with carboplatin and paclitaxel ...
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment sensitivity would be valuable in order to identify responders from non-responders. In this study we describe the non-invasive PET imaging of glucose uptake and cell proliferation using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3-[(18)F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of human ovarian cancer treated with carboplatin and paclitaxel ...
Inclusion Criteria: - Histologically-confirmed ovarian, fallopian, or primary peritoneal carcinoma of epithelial origin - Recurrent or persistent advanced disease - Have measurable disease - Undergone at least two courses of therapy with a platinum drug (cisplatin or carboplatin) and have responded to the first of those courses of therapy as determined by either Response Evaluation Criteria in Solid Tumors (RECIST) or Gynecologic Cancer Intergroup (GCIG) criteria - Disease relapse as determined by either RECIST or GCIG criteria within 6 months of completion of the second or greater course of platinum therapy using a 2-, 3- or 4-weekly regimen and platinum-free interval of no greater than 6 months at the time of enrollment, being the time taken from the last day of platinum therapy - Any number of previous courses of platinum therapy or non-platinum therapy - Likely to survive at least 3 months - Karnofsky performance score of at least 60% - Have adequate physiological function without evidence ...
This trial is investigating the efficacy, tolerability and quality-of-life effects of bevacizumab [Avastin] in combination with carboplatin or paclitaxel, in
The FDA requires all potential medication risks for CARBOPLATIN (injection, solution) be disclosed to consumers, no matter how rare. Here are the warnings and precautions for Carboplatin.
International Scholarly Research Notices is a peer-reviewed, Open Access journal covering a wide range of subjects in science, technology, and medicine. The journals Editorial Board as well as its Table of Contents are divided into 108 subject areas that are covered within the journals scope.
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in H
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel, work in different ways to stop tumor cells from dividing so the
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..
Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks ...
Other scholarly publications - Abstracts - (continued) 73. Morrison V, Weller E, Haberman TM, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne R, Woda B, Fisher R, Peterson B, Horning SJ: Maintenance rituximab (MR) versus observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL) patients: An intergroup E4494/C9793 update. Proc of the American Society of Clinical Oncology: #8011. (2007). 74. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Chen R, Treat J, Obasaju CK, Schiller JH: Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18s):LBA7516. 75. Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN : A phase II trial of carboplatin and ABI-007 in patients with ...
4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. METHODS Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without distant organ metastases were eligible. Patients with locally advanced disease from mediastinal, celiac, portal and gastric lymphadenopathy were eligible. Surgical resection was not required. Clinical complete response was defined as no tumor on postreatment endoscopic biopsy. Patients received cetuximab, 400mg/m2 week #1 then 250 mg/m2/week for 5 weeks, paclitaxel, 50 mg/m2/week, and carboplatin, AUC =2 weekly for 6 weeks, with concurrent 50.4 Gy radiation. RESULTS Thirty-seven patients have been entered. The median
Longer Term Follow-Up Data with Mercks KEYTRUDA in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small C
This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs
An open-label, dose-finding study to evaluate the safety and pharmacokinetics of AMG 706 with Carboplatin/Paclitaxel, AMG 706 with Panitumumab and AMG 706 with Panitumumab and Carboplatin/Paclitaxel in the treatment of subjects with advanced non-small cell lung ...
The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, antitumour properties and potential biochemical selectivities. It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, J …
Evidence for dose modifications is limited, and the recommendations made on eviQ are intended as a guide only. They are generally conservative with an emphasis on safety. Any dose modification should be based on clinical judgement, and the individual patients situation including but not limited to treatment intent (curative vs palliative), the antineoplastic regimen (single versus combination therapy versus chemotherapy versus immunotherapy), biology of the cancer (site, size, mutations, metastases), other treatment related side effects, additional co-morbidities, performance status and patient preferences. Suggested dose modifications are based on clinical trial findings, product information and reference committee consensus. Non-haematological gradings are based on Common Terminology Criteria for Adverse Events (CTCAE) unless otherwise specified. Renal and hepatic dose modifications have been standardised where possible. For more information see dosing considerations & disclaimer. ...
Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of
My husband is facing 2 HDC with Carboplatin for relapsed yolk sac after 14 years being clear. After 4TIPs AFP fell from 88000 to 650, mass in the liver shrank twice to 4 cm, lungs are clear, RPL nodes apart from cloud around IVC are normal size, cloud has shrunk from 8cm to 6cm, IVC seems to be less